GRAIL expects an FDA decision on its Galleri multi-cancer blood test in early 2027. Demand is rising, but evidence that it reduces cancer deaths remains lacking.
GRAIL Expects FDA Decision on Galleri Multi-Cancer Blood Test by Early 2027 as Quarterly Tests Top 56,000
by | Nov 6, 2026 | Uncategorized | 0 comments
Recent Comments